Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neoantigen dendritic cell vaccine (National Cancer Centre, Singapore)
- Development stage
- Unknown
- Lead developer
- National Cancer Centre Singapore
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The neoantigen dendritic cell vaccine developed by the National Cancer Centre, Singapore, is an autologous cell-based immunotherapy designed for the adjuvant treatment of resected hepatocellular carcinoma (HCC) and colorectal cancer liver metastases (CRLM). The vaccine is produced by identifying unique, patient-specific tumor mutations (neoantigens) through genomic sequencing of the resected tumor tissue. These neoantigens are then used to pulse the patient's own harvested dendritic cells, which are matured and re-administered via intra-dermal injection. The goal is to prime and activate the patient's T-cells to recognize and eliminate residual micrometastatic disease. In clinical development (e.g., NCT04912765), this vaccine is evaluated in combination with the immune checkpoint inhibitor nivolumab to synergistically enhance the anti-tumor immune response.
- Other names
- NA DC vaccineNeoantigen DC VaccineNeoantigen Dendritic Cell Vaccine
02
Targets
neoantigen-MHC (Patient-specific tumor neoantigen-MHC complexes recognized by T cell receptors)
Beyond the preview
Go deeper on neoantigen dendritic cell vaccine (National Cancer Centre, Singapore).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neoantigen dendritic cell vaccine (National Cancer Centre, Singapore).